NeuPath Health Launches Arthrosamid® for Knee Osteoarthritis
NeuPath Health Launches Arthrosamid® for Knee Osteoarthritis NeuPath Health Inc. (TSXV: NPTH) (“NeuPath” or the “Company”), a leading provider of chronic pain treatment through its extensive network of clinics, has…
Xeris Biopharma Reports Record Q4 and Full-Year 2024 Results, Sets 2025 Guidance
Xeris Biopharma Reports Record Q4 and Full-Year 2024 Results, Sets 2025 Guidance Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a rapidly growing biopharmaceutical company dedicated to improving patient lives by developing…
Orbital Therapeutics Welcomes Biopharma Leader Geno Germano to Board of Directors
Orbital Therapeutics Strengthens Leadership with the Appointment of Biopharma Veteran Geno Germano to Its Board of Directors Orbital Therapeutics, a pioneering biotechnology company focused on advancing RNA-based medicines to address…
Stevanato Group Achieves Record €1.1 Billion Revenue in Fiscal Year 2024
Stevanato Group Achieves Record €1.1 Billion Revenue in Fiscal Year 2024 Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the…
Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy
Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy Italfarmaco S.p.A., a global pharmaceutical company dedicated to developing innovative treatments for rare diseases, has provided a comprehensive update on the regulatory…
Leading Cancer Center Adopts Abridge AI for Oncology Documentation
Leading Cancer Center Adopts Abridge AI for Oncology Documentation Abridge, a leader in AI-driven clinical documentation solutions, has announced an extensive rollout of its AI platform at Memorial Sloan Kettering…
CB Capital Gives Estrella Immunopharma (ESLA) Buy Rating, $14 Target
Estrella Immunopharma Receives Buy Rating from CB Capital Partners with a $14.00 Price Target Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company pioneering the development…
Alnylam Announces Retirement of Co-Founder and Esteemed Board Member Dr. Phillip A. Sharp
Alnylam Announces Retirement of Co-Founder and Esteemed Board Member Dr. Phillip A. Sharp Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the pioneering leader in RNA interference (RNAi) therapeutics, today announced the retirement…
Bicycle Therapeutics Announces Inducement Grants
Bicycle Therapeutics Announces Inducement Grants Bicycle Therapeutics plc (NASDAQ: BCYC), a pioneering biotechnology company focused on developing a new class of therapeutics known as Bicycle® molecules, announced that on March…
LEO Pharma Survey: Chronic Hand Eczema Misunderstood and Undermanaged
LEO Pharma Survey: Chronic Hand Eczema Misunderstood and Undermanaged LEO Pharma Survey Highlights Widespread Misunderstanding and Inadequate Management of Chronic Hand Eczema Among Dermatology Providers A recent survey commissioned by…
Orbis Medicines Appoints Industry Veteran Mikael Dolsten as Board Chair
Orbis Medicines Appoints Industry Veteran Mikael Dolsten as Board Chair Orbis Medicines, a pioneering leader in oral macrocycle drug discovery, has announced the appointment of Mikael Dolsten, M.D., Ph.D., as…
FDA Accepts sBLA for Genentech’s Gazyva in Lupus Nephritis
FDA Accepts sBLA for Genentech’s Gazyva in Lupus Nephritis Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced that the U.S. Food and Drug Administration…